AbbVie, Teneobio, and its affiliate TeneoOne have entered a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma.
Samsung Bioepis has announced its expansion in mainland China through a licensing agreement with C-Bridge Capital.
Evotec and Galapagos have announced a global collaboration focused on a novel target for fibrosis and other indications.
Ligand Pharmaceuticals has entered into a worldwide OmniAb partnership with Genagon Therapeutics AB, an immuno-oncology focused biotech located in Sweden.
BioMotiv, a drug development accelerator associated with The Harrington Project for Discovery & Development, and researchers from Rutgers, The State University of New Jersey, announced the formation of a new biotech start-up, TamRx.
Frazier Healthcare Partners has launched Recida Therapeutics, a biopharmaceutical company focused on the development of novel therapeutics for serious antibiotic-resistant infections.
GlaxoSmithKline (GSK) and Merck will develop and commercialize novel immunotherapy to treat multiple cancers, under €3.7bn worth deal.
Frontier IP, a specialist in commercialising university intellectual property, today announces portfolio company Amprologix (the "Company") has won a contract worth £1.2 million funded by the UK Department for Health and Social Care to accelerate development and scale up its lead antibiotic candidate to tackle antimicrobial resistant MRSA and related superbugs.
IQVIA has announced the launch of IQVIA Biotech and its new approach to delivering tailored clinical and commercial solutions for small biotech and biopharma companies.
Fortress Biotech, a biopharmaceutical company focused on acquiring, developing and commercializing pharmaceutical and biotechnology products, announced that Caelum Biosciences has signed a strategic agreement with Alexion Pharmaceuticals to advance the development of CAEL-101 for light chain (AL) amyloidosis.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.